Last 151.75 GBp
Change Today -0.50 / -0.33%
Volume 72.7K
VEC On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:35 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

vectura group plc (VEC) Snapshot

Open
149.00 GBp
Previous Close
152.25 GBp
Day High
152.25 GBp
Day Low
149.00 GBp
52 Week High
02/19/14 - 171.50 GBp
52 Week Low
10/16/14 - 113.75 GBp
Market Cap
610.8M
Average Volume 10 Days
412.9K
EPS TTM
-0.02 GBp
Shares Outstanding
402.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VECTURA GROUP PLC (VEC)

Related News

No related news articles were found.

vectura group plc (VEC) Related Businessweek News

No Related Businessweek News Found

vectura group plc (VEC) Details

Vectura Group plc researches, develops, and commercialises novel therapeutic products and drug delivery systems for the treatment of airways-related diseases. The company offers ADVATE for the treatment of haemophilia A; Adept for the treatment of surgical adhesions; Extraneal for the treatment of peritoneal dialysis; Seebri Breezhaler and Ultibro Breezhaler for the treatment of chronic obstructive pulmonary disease (COPD); and AirFlusal Forspiro for the treatment of asthma and COPD, as well as Asmasal and Asmabec for the treatment of asthma. Its full development stage products include VR315, VR506, and VR632 for the treatment of asthma. The company’s Phase III clinical stage products include NVA237 and QVA149 for the treatment of COPD; VR475 for the treatment severe adult asthma; and VR876 for the treatment of pulmonary hypertension. Its Phase II clinical stage products comprise VR647 for the treatment of paediatric asthma; VR179 for the treatment of cystic fibrosis; VR736 for the treatment severe influenza; and SB010 for the treatment of asthma and other respiratory diseases. The company’s Phase I clinical stage products include VR475 for the treatment severe adult asthma; VR465 for the treatment for respiratory syncytial virus infection. Its pre-clinical stage products include VR588 and VR942 for the treatment of inflammatory airway diseases; and VR611 for the treatment of airways inflammatory and chronic cough diseases. The company also provides drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to enhance the performance of DPI products; PowderMax technology that applies PowderHale approach to spectrum of drug substances; and ParticleMax technology to create a new generation of formulations. In addition, it provides Gryohaler, lever-operated, open-inhale-close, AKITA Jet, APIXNEB, and FOX devices. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

281 Employees
Last Reported Date: 07/30/14
Founded in 1997

vectura group plc (VEC) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 674.0K GBP
Chief Operations Officer, Director and Presid...
Total Annual Compensation: 482.0K GBP
Compensation as of Fiscal Year 2014.

vectura group plc (VEC) Key Developments

Vectura Group plc Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:30 PM

Vectura Group plc Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 04:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Christopher Paul Blackwell, Chief Executive Officer and Executive Director.

Vectura Group plc Enters into Global Development and License Agreement with Janssen Biotech

Vectura Group plc announced that the company has entered into a global development and license agreement with Janssen Biotech Inc. for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD. The collaboration will focus initially on the development of a Phase II candidate and has the potential to include additional clinical-stage candidates. The collaboration will leverage Vectura's expertise and proprietary dry powder inhaler technologies in the development of inhaled therapeutics. Vectura will apply its delivery technologies to develop Janssen's pulmonary products into late-stage clinical development and commercialization. Janssen will lead the clinical development programmes, with Vectura taking responsibility for pharmaceutical development and preparation for Phase II clinical trials. The deal comprises upfront and development milestones and a tiered royalty on net sales. Financial terms of the agreement are not disclosed.

Vectura Group plc Announces Positive Phase IIb/III Results for VR475 in Asthma

Vectura Group plc announced the publication in the European Respiratory Journal (ERJ) of a clinical study demonstrating positive results from its Phase IIb/III (Acti-AICS-001) clinical trial investigating the efficacy, safety and tolerability of VR475 in the treatment of oral corticosteroid (OCS)-dependent (GINA Step 5) asthma patients. VR475 is an investigational drug/device combination product that delivers an approved corticosteroid, budesonide, to the lungs via Vectura's AKITA Jet inhalation system, controlled by a Smart Card. The system is designed to deliver budesonide to the small airways of the lungs more efficiently than conventional delivery systems. The study compared the effects of two doses of budesonide delivered by AKITA Jet inhalation system (AICS-BUD 1 mg and AICS-BUD 0.5 mg) with placebo and budesonide delivered by conventional nebuliser (CN-BUD 1 mg). These treatments were added to standard severe asthma therapies for 18 weeks. Main study findings include: Significantly more patients successfully reducing OCS dose by more than 50% whilst maintaining asthma stability compared with placebo (primary endpoint; AICS-BUD 1 mg 80% vs placebo 63%; p=0.02) - Mean reduction in OCS dose was 7.1 mg for AICS Bud 1 mg and 3.6 mg for placebo; p=0.005 - Improved lung function for both AICS-BUD doses but not placebo or CN-BUD 1 mg (FEV1 improvement from baseline to week 18: AICS-Bud 1 mg 239 mL; p<0.001); AICS-Bud 0.5 mg (126 mL; p=0.01), placebo (93 mL; p=0.36); CN-Bud (137 mL; p=0.18) - Fewer patients experienced asthma exacerbations in the AICS-BUD 1 mg treated group (AICS-BUD 1 mg, 7.5%) compared with placebo (17.5%) and CN-BUD 1 mg group (22.5%) - Significantly fewer days were spent in hospital in relation to total study duration in the AICS-Bud 1 mg arm (5 of 13,152 patient treatment days vs placebo (49 of 6,328 days), p<0.001). All treatments were well tolerated. VR475 resulted in significant and meaningful OCS reduction in OCS-dependent asthma patients while improving pulmonary function and maintaining asthma exacerbation control.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VEC:LN 151.75 GBp -0.50

VEC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Skyepharma PLC 262.50 GBp +1.75
View Industry Companies
 

Industry Analysis

VEC

Industry Average

Valuation VEC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.5x
Price/Book 2.6x
Price/Cash Flow 90.1x
TEV/Sales 14.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VECTURA GROUP PLC, please visit www.vectura.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.